{"transactions":[{"id":4634300,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-10-03T00:30:31.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":50246,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The option was granted to and is held by Futurum through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":344983,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":50246},"source":{"system":"sec-edgar","filing":"0001193125-26-412431","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526412431/ownership.xml","form_type":"4"}},{"id":4634299,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-10-03T00:30:31.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":50246,"price":25.03,"value":1257657.38,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.10 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-412431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526412431/ownership.xml","form_type":"4"}},{"id":4634298,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-10-03T00:30:31.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":50246,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum."}],"balance_after":119548,"source":{"system":"sec-edgar","filing":"0001193125-26-412431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526412431/ownership.xml","form_type":"4"}},{"id":4618117,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-15T20:30:04.000Z","date":"2026-09-14","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":22.65,"value":226500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person.  Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person."}],"balance_after":792923,"source":{"system":"sec-edgar","filing":"0001193125-26-391985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526391985/ownership.xml","form_type":"4"}},{"id":4613394,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26570,"kind":"person","name":"Smither John W","position":1,"cik":"0001559583","reported_name":"Smither John W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:30:03.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":1600,"price":25.32,"value":40512.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction reflects a sale of ordinary shares to generate proceeds to satisfy the Reporting Person's tax obligations in connection with the prior vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.24 to $25.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 8,040 ordinary shares subject to restricted stock unit awards that remain subject to vesting."}],"balance_after":8760,"source":{"system":"sec-edgar","filing":"0001193125-26-386508","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526386508/ownership.xml","form_type":"4"}},{"id":2413,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1827,"kind":"person","name":"Gunning Robert William","position":1,"cik":"0002148571","reported_name":"Gunning Robert William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Controller"}}],"security":"Option (right to buy)","published_at":"2026-09-03T20:30:05.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying the option will vest on August 10, 2026, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":14000,"derivative":{"exercise_price":24.92,"expiration_date":"2036-08-31","underlying":"Ordinary Shares","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001193125-26-381953","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2148571/000119312526381953/ownership.xml","form_type":"4"}},{"id":2412,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1827,"kind":"person","name":"Gunning Robert William","position":1,"cik":"0002148571","reported_name":"Gunning Robert William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Controller"}}],"security":"Ordinary Shares","published_at":"2026-09-03T20:30:05.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, September 10, 2026, subject to the Reporting Person's continued service through each such date."}],"balance_after":3200,"source":{"system":"sec-edgar","filing":"0001193125-26-381953","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2148571/000119312526381953/ownership.xml","form_type":"4"}},{"id":676283,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-08-25T20:30:07.000Z","date":"2026-08-24","kind":"exercise","planned":true,"acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The option was granted to and is held by Futurum through PoolCo for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":395229,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-365202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526365202/ownership.xml","form_type":"4"}},{"id":676282,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-08-25T20:30:07.000Z","date":"2026-08-24","kind":"sale","planned":true,"acquired":false,"shares":125000,"price":26.91,"value":3363750.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.72 to $27.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-365202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526365202/ownership.xml","form_type":"4"}},{"id":676281,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-08-25T20:30:07.000Z","date":"2026-08-24","kind":"exercise","planned":true,"acquired":true,"shares":125000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum."}],"balance_after":194302,"source":{"system":"sec-edgar","filing":"0001193125-26-365202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526365202/ownership.xml","form_type":"4"}},{"id":704806,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-07-22T20:05:04.000Z","date":"2026-07-20","kind":"exercise","planned":true,"acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on January 1, 2024. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":70494,"derivative":{"exercise_price":11.17,"expiration_date":"2034-01-01","underlying":"Ordinary Shares","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001193125-26-312387","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526312387/ownership.xml","form_type":"4"}},{"id":704805,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-07-22T20:05:04.000Z","date":"2026-07-20","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on May 18, 2023. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":11.9,"expiration_date":"2033-05-18","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-312387","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526312387/ownership.xml","form_type":"4"}},{"id":704804,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-07-22T20:05:04.000Z","date":"2026-07-20","kind":"sale","planned":true,"acquired":false,"shares":2915,"price":31.71,"value":92434.65,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $31.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."}],"balance_after":24353,"source":{"system":"sec-edgar","filing":"0001193125-26-312387","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526312387/ownership.xml","form_type":"4"}},{"id":704803,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-07-22T20:05:04.000Z","date":"2026-07-20","kind":"sale","planned":true,"acquired":false,"shares":31885,"price":31.05,"value":990029.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."}],"balance_after":27268,"source":{"system":"sec-edgar","filing":"0001193125-26-312387","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526312387/ownership.xml","form_type":"4"}},{"id":704802,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-07-22T20:05:04.000Z","date":"2026-07-20","kind":"sale","planned":true,"acquired":false,"shares":70200,"price":29.96,"value":2103192.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.57 to $30.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."}],"balance_after":59153,"source":{"system":"sec-edgar","filing":"0001193125-26-312387","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526312387/ownership.xml","form_type":"4"}},{"id":704801,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-07-22T20:05:04.000Z","date":"2026-07-20","kind":"exercise","planned":true,"acquired":true,"shares":80000,"price":11.17,"value":893600.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."}],"balance_after":129353,"source":{"system":"sec-edgar","filing":"0001193125-26-312387","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526312387/ownership.xml","form_type":"4"}},{"id":704800,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-07-22T20:05:04.000Z","date":"2026-07-20","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":11.9,"value":297500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."}],"balance_after":49353,"source":{"system":"sec-edgar","filing":"0001193125-26-312387","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526312387/ownership.xml","form_type":"4"}},{"id":727888,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-06-24T20:10:03.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on May 18, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":35000,"derivative":{"exercise_price":11.9,"expiration_date":"2033-05-18","underlying":"Ordinary Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-281062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526281062/ownership.xml","form_type":"4"}},{"id":727887,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-06-24T20:10:03.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":43134,"derivative":{"exercise_price":10.9,"expiration_date":"2033-01-01","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-281062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526281062/ownership.xml","form_type":"4"}},{"id":727886,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:10:03.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":300,"price":30.73,"value":9219.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."}],"balance_after":24353,"source":{"system":"sec-edgar","filing":"0001193125-26-281062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526281062/ownership.xml","form_type":"4"}},{"id":727885,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:10:03.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":39700,"price":30.2,"value":1198940.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."}],"balance_after":24653,"source":{"system":"sec-edgar","filing":"0001193125-26-281062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526281062/ownership.xml","form_type":"4"}},{"id":727884,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:10:03.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":11.9,"value":178500.0,"ownership":{"direct":true},"balance_after":64353,"source":{"system":"sec-edgar","filing":"0001193125-26-281062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526281062/ownership.xml","form_type":"4"}},{"id":727883,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:10:03.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":10.9,"value":272500.0,"ownership":{"direct":true},"balance_after":49353,"source":{"system":"sec-edgar","filing":"0001193125-26-281062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526281062/ownership.xml","form_type":"4"}},{"id":762119,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-05-27T20:30:12.000Z","date":"2026-05-26","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":68134,"derivative":{"exercise_price":10.9,"expiration_date":"2033-01-01","underlying":"Ordinary Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-241983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526241983/ownership.xml","form_type":"4"}},{"id":762118,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-05-27T20:30:12.000Z","date":"2026-05-26","kind":"exercise","planned":true,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date."}],"balance_after":80015,"derivative":{"exercise_price":10,"expiration_date":"2032-11-22","underlying":"Ordinary Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-241983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526241983/ownership.xml","form_type":"4"}},{"id":762117,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-05-27T20:30:12.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":65000,"price":35.69,"value":2319850.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.12 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."}],"balance_after":24353,"source":{"system":"sec-edgar","filing":"0001193125-26-241983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526241983/ownership.xml","form_type":"4"}},{"id":762116,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-05-27T20:30:12.000Z","date":"2026-05-26","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":10.9,"value":54500.0,"ownership":{"direct":true},"balance_after":89353,"source":{"system":"sec-edgar","filing":"0001193125-26-241983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526241983/ownership.xml","form_type":"4"}},{"id":762115,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-05-27T20:30:12.000Z","date":"2026-05-26","kind":"exercise","planned":true,"acquired":true,"shares":60000,"price":10,"value":600000.0,"ownership":{"direct":true},"balance_after":84353,"source":{"system":"sec-edgar","filing":"0001193125-26-241983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526241983/ownership.xml","form_type":"4"}},{"id":846466,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-12T20:25:23.000Z","date":"2026-03-11","kind":"sale","planned":false,"acquired":false,"shares":446,"price":31.23,"value":13928.58,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":10360,"source":{"system":"sec-edgar","filing":"0001193125-26-104239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526104239/ownership.xml","form_type":"4"}},{"id":846465,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-12T20:25:23.000Z","date":"2026-03-11","kind":"sale","planned":false,"acquired":false,"shares":44173,"price":30.41,"value":1343300.93,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":10806,"source":{"system":"sec-edgar","filing":"0001193125-26-104239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526104239/ownership.xml","form_type":"4"}},{"id":851340,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2026-03-11T00:58:01.000Z","date":"2026-03-09","kind":"other","planned":false,"acquired":false,"shares":44619,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":11.5,"exercise_date":"2022-12-22","expiration_date":"2027-11-23","underlying":"Ordinary Shares","underlying_shares":44619},"source":{"system":"sec-edgar","filing":"0001193125-26-100798","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526100798/ownership.xml","form_type":"4"}},{"id":851339,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-11T00:58:01.000Z","date":"2026-03-09","kind":"other","planned":false,"acquired":true,"shares":44619,"price":11.5,"value":513118.5,"ownership":{"direct":true},"balance_after":54979,"source":{"system":"sec-edgar","filing":"0001193125-26-100798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526100798/ownership.xml","form_type":"4"}},{"id":851338,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-11T00:58:01.000Z","date":"2026-03-06","kind":"sale","planned":false,"acquired":false,"shares":28186,"price":29.41,"value":828950.26,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by LGLange III Trust DTD10 (the \"Trust\") for the benefit of the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-100798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526100798/ownership.xml","form_type":"4"}},{"id":853842,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":101409,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The option was granted to and is held by Futurum through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":520229,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":101409},"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853841,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-06","kind":"exercise","planned":true,"acquired":false,"shares":94124,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The option was granted to and is held by Futurum through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":621638,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":94124},"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853840,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-05","kind":"exercise","planned":true,"acquired":false,"shares":104467,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The option was granted to and is held by Futurum through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":715762,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":104467},"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853839,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":101409,"price":30.29,"value":3071678.61,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.80 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853838,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":101409,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":170711,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853837,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":94124,"price":30.32,"value":2853839.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853836,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-06","kind":"exercise","planned":true,"acquired":true,"shares":94124,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":163426,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853835,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":104467,"price":30.3,"value":3165350.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853834,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-05","kind":"exercise","planned":true,"acquired":true,"shares":104467,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":173769,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":874641,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-03-02T23:08:05.000Z","date":"2026-03-02","kind":"exercise","planned":false,"acquired":false,"shares":443707,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":239267,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":443707},"source":{"system":"sec-edgar","filing":"0001193125-26-085947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526085947/ownership.xml","form_type":"4"}},{"id":874640,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-02T23:08:05.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":443707,"price":33.25,"value":14753257.75,"ownership":{"direct":true},"balance_after":174144,"source":{"system":"sec-edgar","filing":"0001193125-26-085947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526085947/ownership.xml","form_type":"4"}},{"id":874639,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-02T23:08:05.000Z","date":"2026-03-02","kind":"exercise","planned":false,"acquired":true,"shares":443707,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."}],"balance_after":617851,"source":{"system":"sec-edgar","filing":"0001193125-26-085947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526085947/ownership.xml","form_type":"4"}},{"id":879919,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-26","kind":"exercise","planned":true,"acquired":false,"shares":183332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":682974,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":183332},"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879918,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":58253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":866306,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":58253},"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879917,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":false,"shares":64708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":924559,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":64708},"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879916,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":17924,"price":34.44,"value":617302.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The amount reported in Column 5 reflects the transfer of 285,715 ordinary shares from the Reporting Person to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the \"GRAT\") on February 26, 2026, which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934. The Reporting Person is the sole annuitant and trustee of the GRAT."}],"balance_after":174144,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879915,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":165408,"price":33.63,"value":5562671.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":477783,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879914,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-26","kind":"exercise","planned":true,"acquired":true,"shares":183332,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."}],"balance_after":643191,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879913,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":1300,"price":36.68,"value":47684.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.58 to $36.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":459859,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879912,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":10436,"price":35.96,"value":375278.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.57 to $36.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":461159,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879911,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":46517,"price":35.11,"value":1633211.87,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.57 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":471595,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879910,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":58253,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."}],"balance_after":518112,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879909,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":3161,"price":36.46,"value":115250.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.43 to $36.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":459859,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879908,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":61547,"price":36.13,"value":2223693.11,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.43 to $36.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":463020,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":879907,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-27T02:40:55.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":true,"shares":64708,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."}],"balance_after":524567,"source":{"system":"sec-edgar","filing":"0001193125-26-078718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/ownership.xml","form_type":"4"}},{"id":885368,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-24T21:40:11.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":30789,"price":35.46,"value":1091777.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $35.86 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":53500,"source":{"system":"sec-edgar","filing":"0001193125-26-067260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526067260/ownership.xml","form_type":"4"}},{"id":885367,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-24T21:40:11.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":14692,"price":35,"value":514220.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.24 to $35.23 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":84289,"source":{"system":"sec-edgar","filing":"0001193125-26-067260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526067260/ownership.xml","form_type":"4"}},{"id":927992,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-01-29T21:40:24.000Z","date":"2026-01-28","kind":"exercise","planned":true,"acquired":false,"shares":32612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":73134,"derivative":{"exercise_price":10.9,"expiration_date":"2033-01-01","underlying":"Ordinary Shares","underlying_shares":32612},"source":{"system":"sec-edgar","filing":"0001193125-26-029526","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526029526/ownership.xml","form_type":"4"}},{"id":927991,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-01-29T21:40:24.000Z","date":"2026-01-27","kind":"exercise","planned":true,"acquired":false,"shares":39816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":105746,"derivative":{"exercise_price":10.9,"expiration_date":"2033-01-01","underlying":"Ordinary Shares","underlying_shares":39816},"source":{"system":"sec-edgar","filing":"0001193125-26-029526","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526029526/ownership.xml","form_type":"4"}},{"id":927990,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-29T21:40:24.000Z","date":"2026-01-28","kind":"sale","planned":true,"acquired":false,"shares":32612,"price":31.8,"value":1037061.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $32.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":24353,"source":{"system":"sec-edgar","filing":"0001193125-26-029526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526029526/ownership.xml","form_type":"4"}},{"id":927989,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-29T21:40:24.000Z","date":"2026-01-28","kind":"exercise","planned":true,"acquired":true,"shares":32612,"price":10.9,"value":355470.8,"ownership":{"direct":true},"balance_after":56965,"source":{"system":"sec-edgar","filing":"0001193125-26-029526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526029526/ownership.xml","form_type":"4"}},{"id":927988,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-29T21:40:24.000Z","date":"2026-01-27","kind":"sale","planned":true,"acquired":false,"shares":39816,"price":32.62,"value":1298797.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.29 to $32.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":24353,"source":{"system":"sec-edgar","filing":"0001193125-26-029526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526029526/ownership.xml","form_type":"4"}},{"id":927987,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-29T21:40:24.000Z","date":"2026-01-27","kind":"exercise","planned":true,"acquired":true,"shares":39816,"price":10.9,"value":433994.4,"ownership":{"direct":true},"balance_after":64169,"source":{"system":"sec-edgar","filing":"0001193125-26-029526","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526029526/ownership.xml","form_type":"4"}},{"id":930157,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-01-27T22:38:55.000Z","date":"2026-01-26","kind":"exercise","planned":true,"acquired":false,"shares":34400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":145562,"derivative":{"exercise_price":10.9,"expiration_date":"2033-01-01","underlying":"Ordinary Shares","underlying_shares":34400},"source":{"system":"sec-edgar","filing":"0001193125-26-025012","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526025012/ownership.xml","form_type":"4"}},{"id":930156,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Option (right to buy)","published_at":"2026-01-27T22:38:55.000Z","date":"2026-01-23","kind":"exercise","planned":true,"acquired":false,"shares":38172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":179962,"derivative":{"exercise_price":10.9,"expiration_date":"2033-01-01","underlying":"Ordinary Shares","underlying_shares":38172},"source":{"system":"sec-edgar","filing":"0001193125-26-025012","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526025012/ownership.xml","form_type":"4"}},{"id":930155,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-27T22:38:55.000Z","date":"2026-01-26","kind":"sale","planned":true,"acquired":false,"shares":309,"price":33.45,"value":10336.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.40 to $33.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":24353,"source":{"system":"sec-edgar","filing":"0001193125-26-025012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526025012/ownership.xml","form_type":"4"}},{"id":930154,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-27T22:38:55.000Z","date":"2026-01-26","kind":"sale","planned":true,"acquired":false,"shares":34091,"price":32.77,"value":1117162.07,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.40 to $33.38 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":24662,"source":{"system":"sec-edgar","filing":"0001193125-26-025012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526025012/ownership.xml","form_type":"4"}},{"id":930153,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-27T22:38:55.000Z","date":"2026-01-26","kind":"exercise","planned":true,"acquired":true,"shares":34400,"price":10.9,"value":374960.0,"ownership":{"direct":true},"balance_after":58753,"source":{"system":"sec-edgar","filing":"0001193125-26-025012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526025012/ownership.xml","form_type":"4"}},{"id":930152,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-27T22:38:55.000Z","date":"2026-01-23","kind":"sale","planned":true,"acquired":false,"shares":12767,"price":34.37,"value":438801.79,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.06 to $34.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":24353,"source":{"system":"sec-edgar","filing":"0001193125-26-025012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526025012/ownership.xml","form_type":"4"}},{"id":930151,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-27T22:38:55.000Z","date":"2026-01-23","kind":"sale","planned":true,"acquired":false,"shares":25405,"price":33.44,"value":849543.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.06 to $34.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":37120,"source":{"system":"sec-edgar","filing":"0001193125-26-025012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526025012/ownership.xml","form_type":"4"}},{"id":930150,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":29181,"kind":"person","name":"Kooij Louise Frederika","position":1,"cik":"0002004379","reported_name":"Kooij Louise Frederika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-27T22:38:55.000Z","date":"2026-01-23","kind":"exercise","planned":true,"acquired":true,"shares":38172,"price":10.9,"value":416074.8,"ownership":{"direct":true},"balance_after":62525,"source":{"system":"sec-edgar","filing":"0001193125-26-025012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2004379/000119312526025012/ownership.xml","form_type":"4"}},{"id":933509,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69005,"kind":"person","name":"Somaiya Mayur Ian","position":1,"cik":"0001760303","reported_name":"Somaiya Mayur Ian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2026-01-22T22:24:59.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":39784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":662814,"derivative":{"exercise_price":9.26,"expiration_date":"2033-11-01","underlying":"Ordinary Shares","underlying_shares":39784},"source":{"system":"sec-edgar","filing":"0001193125-26-019686","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/ownership.xml","form_type":"4"}},{"id":933508,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69005,"kind":"person","name":"Somaiya Mayur Ian","position":1,"cik":"0001760303","reported_name":"Somaiya Mayur Ian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2026-01-22T22:24:59.000Z","date":"2026-01-20","kind":"exercise","planned":true,"acquired":false,"shares":60216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":702598,"derivative":{"exercise_price":9.26,"expiration_date":"2033-11-01","underlying":"Ordinary Shares","underlying_shares":60216},"source":{"system":"sec-edgar","filing":"0001193125-26-019686","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/ownership.xml","form_type":"4"}},{"id":933507,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69005,"kind":"person","name":"Somaiya Mayur Ian","position":1,"cik":"0001760303","reported_name":"Somaiya Mayur Ian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-22T22:24:59.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":24362,"price":33.8,"value":823435.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were sold in multiple transactions at prices ranging from $33.48 per share to $34.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":58382,"source":{"system":"sec-edgar","filing":"0001193125-26-019686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/ownership.xml","form_type":"4"}},{"id":933506,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69005,"kind":"person","name":"Somaiya Mayur Ian","position":1,"cik":"0001760303","reported_name":"Somaiya Mayur Ian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-22T22:24:59.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":15422,"price":33.25,"value":512781.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were sold in multiple transactions at prices ranging from $32.48 per share to $33.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":82744,"source":{"system":"sec-edgar","filing":"0001193125-26-019686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/ownership.xml","form_type":"4"}},{"id":933505,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69005,"kind":"person","name":"Somaiya Mayur Ian","position":1,"cik":"0001760303","reported_name":"Somaiya Mayur Ian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-22T22:24:59.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":39784,"price":9.26,"value":368399.84,"ownership":{"direct":true},"balance_after":98166,"source":{"system":"sec-edgar","filing":"0001193125-26-019686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/ownership.xml","form_type":"4"}},{"id":933504,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69005,"kind":"person","name":"Somaiya Mayur Ian","position":1,"cik":"0001760303","reported_name":"Somaiya Mayur Ian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-22T22:24:59.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":19604,"price":32.38,"value":634777.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were sold in multiple transactions at prices ranging from $32.29 per share to $32.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":58382,"source":{"system":"sec-edgar","filing":"0001193125-26-019686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/ownership.xml","form_type":"4"}},{"id":933503,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69005,"kind":"person","name":"Somaiya Mayur Ian","position":1,"cik":"0001760303","reported_name":"Somaiya Mayur Ian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-22T22:24:59.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":39712,"price":31.78,"value":1262047.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were sold in multiple transactions at prices ranging from $31.29 per share to $32.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":77986,"source":{"system":"sec-edgar","filing":"0001193125-26-019686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/ownership.xml","form_type":"4"}},{"id":933502,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69005,"kind":"person","name":"Somaiya Mayur Ian","position":1,"cik":"0001760303","reported_name":"Somaiya Mayur Ian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-22T22:24:59.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":900,"price":30.64,"value":27576.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were sold in multiple transactions at prices ranging from $30.17 per share to $30.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":117698,"source":{"system":"sec-edgar","filing":"0001193125-26-019686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/ownership.xml","form_type":"4"}},{"id":933501,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69005,"kind":"person","name":"Somaiya Mayur Ian","position":1,"cik":"0001760303","reported_name":"Somaiya Mayur Ian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-22T22:24:59.000Z","date":"2026-01-20","kind":"exercise","planned":true,"acquired":true,"shares":60216,"price":9.26,"value":557600.16,"ownership":{"direct":true},"balance_after":118598,"source":{"system":"sec-edgar","filing":"0001193125-26-019686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/ownership.xml","form_type":"4"}},{"id":942370,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":36908,"kind":"person","name":"Gulfo Adele M.","position":1,"cik":"0001647102","reported_name":"Gulfo Adele M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-01-10T00:34:36.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."}],"balance_after":15300,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001193125-26-009273","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009273/ownership.xml","form_type":"4"}},{"id":942369,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":36908,"kind":"person","name":"Gulfo Adele M.","position":1,"cik":"0001647102","reported_name":"Gulfo Adele M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:34:36.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":14260,"source":{"system":"sec-edgar","filing":"0001193125-26-009273","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009273/ownership.xml","form_type":"4"}},{"id":942368,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (right to buy)","published_at":"2026-01-10T00:34:21.000Z","date":"2026-01-07","kind":"grant","planned":true,"acquired":true,"shares":364000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":364000,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":364000},"source":{"system":"sec-edgar","filing":"0001193125-26-009272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009272/ownership.xml","form_type":"4"}},{"id":942367,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:34:21.000Z","date":"2026-01-07","kind":"grant","planned":true,"acquired":true,"shares":81000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":459859,"source":{"system":"sec-edgar","filing":"0001193125-26-009272","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009272/ownership.xml","form_type":"4"}},{"id":942366,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:34:21.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":11582,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $35.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":378859,"source":{"system":"sec-edgar","filing":"0001193125-26-009272","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009272/ownership.xml","form_type":"4"}},{"id":942365,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":28834,"kind":"person","name":"Lewis William","position":1,"cik":"0001402051","reported_name":"Lewis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-01-10T00:34:07.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."}],"balance_after":15300,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001193125-26-009271","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009271/ownership.xml","form_type":"4"}},{"id":942364,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":28834,"kind":"person","name":"Lewis William","position":1,"cik":"0001402051","reported_name":"Lewis William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:34:07.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":10360,"source":{"system":"sec-edgar","filing":"0001193125-26-009271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009271/ownership.xml","form_type":"4"}},{"id":942363,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26570,"kind":"person","name":"Smither John W","position":1,"cik":"0001559583","reported_name":"Smither John W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-01-10T00:33:38.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."}],"balance_after":15300,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001193125-26-009270","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009270/ownership.xml","form_type":"4"}},{"id":942362,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26570,"kind":"person","name":"Smither John W","position":1,"cik":"0001559583","reported_name":"Smither John W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:33:38.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":10360,"source":{"system":"sec-edgar","filing":"0001193125-26-009270","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009270/ownership.xml","form_type":"4"}},{"id":942361,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-01-10T00:33:22.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All the shares underlying the option will vest on January 2, 2027, the one-year anniversary of vesting start date, subject to the Reporting Person's continued service through such date."}],"balance_after":15300,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001193125-26-009269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009269/ownership.xml","form_type":"4"}},{"id":942360,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:33:22.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":10360,"source":{"system":"sec-edgar","filing":"0001193125-26-009269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009269/ownership.xml","form_type":"4"}},{"id":942359,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-01-10T00:33:10.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."}],"balance_after":15300,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001193125-26-009268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009268/ownership.xml","form_type":"4"}},{"id":942358,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:33:10.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2026 for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of RSUs on March 28, 2025 to his direct holdings. Such ordinary shares are held directly by LGLange III Trust DTD10 for the benefit of the Reporting Person. The Reporting Person subsequently corrected his indirect holdings on April 21, 2025, and the Reporting Person's indirect holdings reported on May 2, 2025 and June 3, 2025 are correct. This Form 4 reflects the Reporting Person's correct direct holdings."}],"balance_after":10360,"source":{"system":"sec-edgar","filing":"0001193125-26-009268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009268/ownership.xml","form_type":"4"}},{"id":942380,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69682,"kind":"person","name":"van der Kamp Hilde Johanna","position":1,"cik":"0002000565","reported_name":"van der Kamp Hilde Johanna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-01-09T19:34:59.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."}],"balance_after":15300,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001193125-26-009274","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000565/000119312526009274/ownership.xml","form_type":"4"}},{"id":942379,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":69682,"kind":"person","name":"van der Kamp Hilde Johanna","position":1,"cik":"0002000565","reported_name":"van der Kamp Hilde Johanna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-09T19:34:59.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":10360,"source":{"system":"sec-edgar","filing":"0001193125-26-009274","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000565/000119312526009274/ownership.xml","form_type":"4"}},{"id":944831,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-01-07T23:31:26.000Z","date":"2026-01-07","kind":"grant","planned":true,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":115000,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001193125-26-006662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526006662/ownership.xml","form_type":"4"}},{"id":944830,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-07T23:31:26.000Z","date":"2026-01-07","kind":"grant","planned":true,"acquired":true,"shares":25500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":98981,"source":{"system":"sec-edgar","filing":"0001193125-26-006662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526006662/ownership.xml","form_type":"4"}}],"next_cursor":"2026-01-07T23:31:26.000000Z,944830"}